Immune cell functions are tightly regulated by co-inhibitory and co-stimulatory receptors expressed on immune cells. The antagonistic antibodies dominate antibody drug discovery to block negative immune checkpoints and reverse immune resistance of tumors and cancers. Agonistic antibodies have been regarded as promising immune therapeutic agents and a growing number of these agents are making their way through various stages of preclinical and clinical development.
With advanced technologies and years of experience in the antibody development field, Creative Biolabs offers specialized support in the discovery, screening, engineering, and characterization of agonistic antibodies targeting various co-stimulatory receptors.
Agonistic antibodies are antibodies developed against co-stimulatory receptors, which are activated in response to foreign antigens. Due to their high specificity and high affinity, agonistic antibodies act like natural ligands to bind the receptor but mediate more potent downstream signaling. Several agonistic antibodies that target costimulatory molecules, such as CD27, CD40, OX40, 4‑1BB, GITR, ICOS and CD28, have been reported.
For agonistic antibody screening, we employ hybridoma technology coupled with function-based cellular screening assays or phage-display technology to identify potential agonist antibodies targeting a specific target. Besides, we offer agonistic antibody characterization services for clients to characterize the properties of the antibody candidates and to test the efficacy, including but not limited to:
Fig.1 Agonistic antibodies mimic the ligand to engage the costimulatory receptors. (Han, 2019)
In the process of agonistic antibody development, antibody engineering is often required for improved agonistic potential and efficacy. For instance, because the ability of an antibody to induce receptor supercluster formation is critical for costimulatory agonist function, engineering for bispecific antibodies may be particularly useful in activating multicomponent receptor complexes. Besides, factors such as binding epitope, affinity, the interaction of Fc domain with FcγRs can also influence the propensity of an antibody to act as an agonist. At Creative Biolabs, we offer different engineering strategies to optimize the agonistic activity of your antibody, including but not limited to:
For more detailed information, please feel free to contact us or directly send us an online inquiry.